MiNK Therapeutics, Inc. (INKT)
After hours:
| Previous close | 0.8890 |
| Open | 0.8890 |
| Bid | 0.8305 x 100 |
| Ask | 0.9079 x 100 |
| Day's range | 0.8602 - 0.9198 |
| 52-week range | 0.7500 - 3.3400 |
| Volume | |
| Avg. volume | 97,717 |
| Market cap | 30.23M |
| Beta (5Y monthly) | 0.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6500 |
| Earnings date | 11 May 2024 - 15 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
Simply Wall St.This MiNK Therapeutics Insider Increased Their Holding In The Last Year
Viewing insider transactions for MiNK Therapeutics, Inc.'s ( NASDAQ:INKT ) over the last year, we see that insiders...
GlobeNewswireMiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid modelsMiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activation NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseas
ZacksAll You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy
MiNK Therapeutics, Inc. (INKT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
